Guangshengtang: The innovative drug GST-HG131 for the treatment of hepatitis B has been included in the list of breakthrough therapies by the drug evaluation center, but this does not mean that it will be approved for market launch.

Guangshengtang issues a notice on significant abnormal fluctuations in stock trading. The company's hepatitis B treatment innovative drug GST-HG131 has been included in the list of breakthrough therapies by the drug regulatory center, but this does not mean it will be approved for market launch. It is also unlikely to have a major impact on the company's performance in the short term.